IQVIA HOLDINGS INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
IQVIA HOLDINGS INC. (IQV) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $133.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-17
- IQVIA HOLDINGS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $17.00M, a 50.00% decline year-over-year.
- IQVIA HOLDINGS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-09-30 was $17.00M, a 50.00% decline year-over-year.
- IQVIA HOLDINGS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-06-30 was $43.00M, a 437.50% increase year-over-year.
- IQVIA HOLDINGS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-03-31 was $32.00M, a 60.00% increase year-over-year.
- IQVIA HOLDINGS INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $133.00M, a 129.31% increase from fiscal 2024.
- IQVIA HOLDINGS INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $58.00M, a 1.69% decline from fiscal 2023.
- IQVIA HOLDINGS INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $59.00M, a 25.32% decline from fiscal 2022.
- IQVIA HOLDINGS INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $79.00M, a 2.47% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $133.00M 10-K · filed 2026-02-17 | |||
| 2024-12-31 | $58.00M 10-K · filed 2026-02-17 | |||
| 2023-12-31 | $59.00M 10-K · filed 2026-02-17 | |||
| 2022-12-31 | $79.00M 10-K · filed 2025-02-13 | |||
| 2021-12-31 | $81.00M 10-K · filed 2024-02-15 | |||
| 2020-12-31 | $17.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $34.00M derived: sum of 2 quarters · filed 2023-02-15 | $77.00M derived: sum of 3 quarters · filed 2023-02-15 | $109.00M 10-K · filed 2023-02-15 |
| 2020-09-30 | $17.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-22 | $60.00M derived: sum of 2 quarters · filed 2020-10-22 | $92.00M 10-Q · filed 2020-10-22 | $126.00M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-06-30 | $43.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-23 | $75.00M 10-Q · filed 2020-07-23 | $109.00M derived: sum of 3 quarters · filed 2022-02-16 | $143.00M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-03-31 | $32.00M 10-Q · filed 2020-04-30 | $66.00M derived: sum of 2 quarters · filed 2022-02-16 | $100.00M derived: sum of 3 quarters · filed 2022-02-16 | $108.00M derived: sum of 4 quarters · filed 2022-02-16 |
| 2019-12-31 | $34.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $68.00M derived: sum of 2 quarters · filed 2022-02-16 | $76.00M derived: sum of 3 quarters · filed 2022-02-16 | $96.00M 10-K · filed 2022-02-16 |
| 2019-09-30 | $34.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-22 | $42.00M derived: sum of 2 quarters · filed 2020-10-22 | $62.00M 10-Q · filed 2020-10-22 | |
| 2019-06-30 | $8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-23 | $28.00M 10-Q · filed 2020-07-23 | ||
| 2019-03-31 | $20.00M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |